Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections.

Today they announced that the United States Patent and Trademark Office issued U.S. Patent No. 10,988,520 (the ‘520 patent), on April 27, 2021 for CF-370, the company’s second potential therapeutic product candidate. The ‘520 patent, which is owned by ContraFect, expires in March of 2039, and is the latest U.S. patent to issue from the company’s DLA patent portfolio.

The ‘520 patent, entitled “Lysin-Antimicrobial Peptide (AMP) Polypeptide Constructs, Lysins, Isolated Polynucleotides Encoding Same and Uses Thereof” contains composition of matter claims covering the CF-370 construct, and claims for methods of treating Gram-negative bacterial infections, including those caused by Pseudomonas aeruginosa (P. aeruginosa), Klebsiella pneumoniae, Acinetobacter baumannii (A. baumannii), Enterobacter cloacae and Escherichia coli.

This patent demonstrates the Company’s commitment to developing an investigational product targeting P. aeruginosa, a Gram-negative pathogen that causes severe infections, including hospital-acquired and ventilator-associated pneumonias and pulmonary exacerbations of cystic fibrosis infections. Gram-negative bacteria have an outer membrane that makes them more resistant to antibiotics. CF-370 has been molecularly engineered to bypass this outer membrane to enable potent antimicrobial activity in human serum in vitro, providing a novel mechanism to potentially address life-threatening P. aeruginosa infections. By killing targeted bacteria upon contact, lysins are fundamentally different than conventional antibiotics.

“With the issuance of this important patent, we continue expanding ContraFect’s strong intellectual property estate covering this new class of antibacterial drugs. We believe that our superiority-based therapeutic approach, led by the Phase 3 exebacase program being developed for Staph aureus bacteremia, has the potential to fundamentally transform the treatment of patients with life-threatening infections. The need for innovative approaches that address the growing scourge of drug-resistant bacterial infectious diseases is well recognized and we believe that our direct lytic agents could be a significant part of the global solution to this issue,” said Roger J. Pomerantz, M.D., President, Chief Executive Officer, and Chairman of ContraFect.

About CF-370:

CF-370 is an investigational first-in-class therapeutic candidate targeting P. aeruginosa, a Gram-negative pathogen. CF-370 has been engineered to bypass the outer membrane of the bacteria and to enable potent activity in human serum. The Company believes this is a significant milestone for direct lytic agents as native lysins are typically unable to penetrate the outer membrane of Gram-negative bacteria and consequently unable to work in vitro in human blood or in animal models. However, based on the proprietary methods the Company has identified and utilizes to engineer lysins, CF-370 has exhibited the hallmark in vitro features of the lysin class, including rapid and potent bactericidal activity, synergy with a broad range of standard of care agents and the eradication of biofilms in preclinical studies. The promising data from animal models support the potential therapeutic utility of CF-370 for the treatment of serious infections caused by P. aeruginosa, including hospital-acquired and ventilator-associated pneumonias and pulmonary exacerbations of cystic fibrosis.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine